Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Krystal Biotech KRYS underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., the report said. China is moving fast to ...

The Food and Drug Administration is projecting a more favorable stance toward biotech, emphasizing streamlined processes and accelerated approvals (“FDA Sends a Bullish Signal to Biotech ...

A US congressional commission has urged lawmakers to take action to counter China’s “frightening” ascent in biotechnology, flagging Chinese firms including WuXi AppTec and BioMap ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Ardelyx Inc. (NASDAQ:ARDX) stands against ...

In biotechnology, precision, iteration and aligned resources are all critical drivers of breakthroughs in gene therapy. I think these same principles can be fundamental for success in other ...